Navigation Links
DePuy ASR Lawsuit Settlement Excludes Many Individuals Who May Have Been Harmed by Devices Included in DePuy ASR Recall, Bernstein Liebhard LLP Reports

New York, New York (PRWEB) November 20, 2013

The proposed settlement of thousands of DePuy ASR lawsuit ( ) claims excludes many individuals who nevertheless may have been harmed by metal-on-metal hip implants included in the 2010 DePuy ASR recall, Bernstein Liebhard LLP reports. According to the proposal, which was unveiled late yesterday in the U.S. District Court, Northern District of Ohio, DePuy ASR recipients not eligible for the settlement include those who have not yet undergone revision surgery to replace their implant, or those whose revision surgeries were performed after August 31, 2013. However, according to court documents, the proposed settlement agreement does not prevent those individuals from filing their own DePuy ASR lawsuits to obtain compensation for injuries allegedly caused by the recalled devices. (In re: DePuy Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation – MDL 2197)

“The proposed DePuy ASR settlement will not provide any compensation for a large portion of those allegedly affected by the DePuy ASR recall. Our Firm will continue to pursue claims on behalf of these individuals,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices, including hundreds of clients in DePuy ASR lawsuits. The Firm is now offering free legal evaluations to individuals not eligible for the proposed settlement, including those who underwent revision surgery after August 31, 2013, or DePuy ASR recipients who have yet to have revision surgery.

DePuy ASR Settlement Proposal
According to a report from The New York Times, the proposed DePuy ASR settlement would resolve about 8,000 of the more than 12,000 product liability claims currently filed in courts around the country related to the recall. However, to take effect, the accord must first be agreed to by 94% of eligible plaintiffs. If it is finalized, the pact is expected to cost Johnson & Johnson and its DePuy Orthopaedics unit roughly $2.5 billion, and provide a base award for each eligible plaintiff of $250,000. Certain factors, including a plaintiff’s prior medical history, could result in a reduction of the base award. However, certain other circumstances, such as multiple revision surgeries, or the occurrence of “certain extraordinary injuries” in the future, could entitle some plaintiffs to a supplemental award.*

A statement issued by DePuy Orthopaedics late yesterday stipulated that the DePuy ASR settlement will apply only to recipients of the recalled hip implants who underwent revision surgery to replace the device prior to August 31, 2013.**

According to a report from, the DePuy ASR recall was issued after data indicated that 12% of the metal-on-metal hips were failing within just five years of implantation. However, more recent data indicates that the actual early failure rate associated with the devices could reach as high as 44%. When they were first launched in the U.S. in 2005, DePuy had promised that the hips could last for 20 years, Bloomberg said.***

Individuals not eligible for the proposed DePuy ASR settlement may still have a claim for compensation. To learn more about the DePuy ASR recall, visit Bernstein Liebhard LLP’s website. For a free review of your potential DePuy ASR lawsuit, please call 800-511-5092.

*, New York Times, November 20, 2013
**, DePuy Orthopaedics, November 19, 2013
***,, November 19, 2013.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Adds Latest Court Update on DePuy Hip Lawsuits
2. DePuy ASR Lawsuit Settlement News: Bernstein Liebhard LLP Comments on Announcement of DePuy ASR Recall Settlement
3. $2.5 Billion Settlement In DePuy ASR Hip Replacement Lawsuits, Reports Wright & Schulte LLC
4. DePuy Settlement Update: Nov. 19 Conference Could Involve ASR Hip Settlement Talks, Rottenstein Law Group LLP Reports
5. US Drug Watchdog Now Urges Recipients Of The Recalled DePuy ASR Hip Implant To Call Them About A Just Announced Settlement If They Are Not Yet Represented By Counsel
6. $4 Billion DePuy ASR Hip Recall Lawsuit Settlement Reportedly Agreed to by Johnson & Johnson Reports Wright & Schulte LLC
7. DePuy ASR Settlement Update: Rottenstein Law Group LLP Comments on $4 Billion DePuy Hip Settlement News
8. Case List Grows Rapidly in Federal DePuy Pinnacle Lawsuit Litigation, as Bernstein Liebhard LLP Notes Over 5,200 Cases Now Filed over All-Metal Hip
9. DePuy ASR Lawsuits Move Forward in New Jersey, With Scheduling of Next Case Management Conference, Bernstein Liebhard LLP Reports
10. DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Comments on Impending Metal-on-Metal Hip Ban in UK Hospitals
11. New Case Management Order in New Jersey DePuy ASR Recall Litigation Extends Discovery to June 2014, More than 650 Metal Hip Lawsuits Filed in Consolidated Proceeding
Post Your Comments:
(Date:11/26/2015)... ... ... The Catalent Applied Drug Delivery Institute today announced a ... selection in early phase drug development. The first of these is to be ... UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... medical opinion process, participated in the 61st annual Employee Benefits Conference. The Employee ... took place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and ... an application server to improve system efficiency and reliability. , The new Q-Suite 6 ... these standards, the system avoids locking itself into a specific piece of software for ...
(Date:11/25/2015)... ... , ... The holiday season is jam-packed with family dinners, ... attendees is of the utmost importance. Whether you are cooking at home for ... a try this holiday season. , Turkey Croquettes ,     Ingredients: , ...
(Date:11/25/2015)... ... 2015 , ... TyloHelo Inc , North America’s largest ... accessories help improve the bather experience in the sauna, and the accessories selected ... purist looking for simplicity in design to accessories that encourage a greater expression ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 Allergan plc (NYSE: ... Rugen Therapeutics, a start-up  biotechnology company focused on ... disorders and funded by the F-Prime Biomedical Research ... into an exclusive collaboration to support the discovery ... Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 USP 800 applies to all ... pharmacists, pharmacy technicians, nurses, physicians, physician assistants, home ... also covers all entities which store, prepare, transport, ... healthcare institutions, patient treatment clinics, physicians, practice facilities, ... --> What is the purpose of ...
(Date:11/25/2015)... 2015 Asia -based ... BioLight and the New Investors will make a direct ... a private placement. The financing will help IOPtima to ... used in the treatment of glaucoma, as well as ... IOPtimate™ system with the U.S. Food and Drug Administration, ...
Breaking Medicine Technology: